TREATMENT OF <em>BRAF</em><sup>V600E</sup> POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT
Anaplastic thyroid cancer is one of the most aggressive and fatal human carcinomas. A significant experience in using various kinase inhibitors for anaplastic thyroid cancer therapy has been accumulated worldwide. The most encouraging results were obtained after using a combination of b-Raf and MEK...
Saved in:
Main Authors: | P. A. Nikiforovich, P. O. Rumiantsev, I. V. Sleptsov, T. V. Ustinova, K. Yu. Slashchuk, S. L. Vorobyev, S. S. Serzhenko, A. Yu. Abrosimov, A. V. Kudryavtseva, A. A. Semenov, R. A. Chernikov, A. A. Polyakov, A. A. Fedenko, L. V. Bolotina, A. A. Paychadze, A. Y. Trushin, A. D. Kaprin, G. S. Zakharova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2020-10-01
|
Series: | Сибирский онкологический журнал |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/1588 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined target therapy (dabrafenib and trametinib) in the treatment of metastatic <i>BRAF</i><sup> V600E </sup>-positive anaplastic thyroid cancer: clinical cases
by: S. S. Lebedev, et al.
Published: (2025-05-01) -
Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report
by: Kosuke Yunoki, et al.
Published: (2021-08-01) -
Vemurafenib resistant melanoma cells acquire mesenchymal stem cell-like properties
by: A. A. Vartanian, et al.
Published: (2019-12-01) -
Distribution of BRAFV600E mutation in cytological samples of thyroid nodules and its clinical application value
by: WANG Lei, JIN Jingjing, YU Na, XIAO Li
Published: (2025-04-01) -
Резистентные к вемурафенибу клетки меланомы приобретают свойства мезенхимальных стволовых клеток
Published: (2019-12-01)